The credit facility will enable Cellectis to support the development of its UCART product candidates pipeline
The credit facility consists of three tranches of €20 million, €15 million, and €5 million respectively, each redeemable in fine in 6 years
The credit facility is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.